Involvement of methylation-associated silencing of formin 2 in colorectal carcinogenesis

Figure 4 Formin 2 promoter hypermethylation mainly occurs in early-stage colon cancer patients. A: Formin 2 (FMN2) promoter methylation level in colorectal cancer (CRC) tissues with (yes) and without (no) lymphovascular invasion, presented as column means with 95%CI, mean connected. (unpaired t-test; normal: n = 45, CRC tissues with and without lymphovascular invasion: n = 231 and n = 107, respectively); B: FMN2 promoter methylation level in CRC tissues with (N1 + N2) and without (N0) regional lymph node metastasis, presented as column means with 95%CI, mean connected (unpaired t-test, Normal: n = 45, CRC tissues with and without regional lymph node metastasis: n = 212 and n = 173, according to the AJCC Cancer Staging Manual); C: FMN2 promoter methylation level in CRC tissues from different stages, presented as column means with 95%CI, mean connected (unpaired t-test; Normal: n = 45, Stages I + II: n = 197, Stages III + IV: n = 172, according to the AJCC Cancer Staging Manual); D: FMN2 promoter methylation level in different organ sites, presented as column means with 95%CI, mean connected; E and F: FMN2 hypermethylation has no effect on the overall survival or disease-free survival of CRC patients.